Literature DB >> 24989016

High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment.

Kyeong-A Kim1, Young-Jun Shin, Muhammad Akram, Eun-Sun Kim, Ko-Woon Choi, Hyewon Suh, Chul-Hoon Lee, Ok-Nam Bae.   

Abstract

Cardiovascular complications are the major causes of death in patients with diabetes mellitus. Several studies have demonstrated that endothelial progenitor cells (EPCs), adult stem cells contributing to the regeneration of vascular endothelium, are dysfunctional under diabetic condition resulting in impaired peripheral circulation and delayed wound healing. In this study, we investigated the cellular alteration of EPCs under high glucose condition, to elucidate the mechanisms underlying diabetes-associated EPC dysfunction. EPCs were isolated from bone marrow and cultured in normal glucose (5.5 mM)- or high glucose (HG; 30 mM)-containing medium. High glucose treated-EPCs showed decreased ability to form tubule-like networks in Matrigel compared to EPCs under normal glucose, which matched well to the clinical observation of diabetic EPC dysfunction. Conversion of LC3-I to LC3-II was increased in EPCs under HG condition, showing that HG induced autophagy in EPCs. Flow cytometric analysis revealed generation of oxidative stress and disruption of mitochondrial permeability in HG exposed EPCs. Increased mitochondrial oxidative stress was also observed by mitochondria-specific superoxide indicator, MitoSOX(TM). Taken together, we demonstrated that autophagy and mitochondrial impairment were induced in EPCs under high glucose condition, giving a new insight into the mechanism underlying dysfunction of diabetic EPCs. We hope that our finding can contribute to the development of a new treatment option for cardiovascular complications in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989016     DOI: 10.1248/bpb.b14-00172

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  31 in total

Review 1.  Stem cell guidance through the mechanistic target of rapamycin.

Authors:  Kenneth Maiese
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

Review 2.  Programming apoptosis and autophagy with novel approaches for diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

3.  mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-03-15

Review 4.  Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2016       Impact factor: 1.990

Review 5.  Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2017       Impact factor: 1.990

Review 6.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

Review 7.  The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Biochem Soc Trans       Date:  2018-03-09       Impact factor: 5.407

Review 8.  Molecular mechanisms associated with diabetic endothelial-erectile dysfunction.

Authors:  Ângela Castela; Carla Costa
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

9.  Hypersplenism: an independent risk factor for myocardial remodeling in chronic heart failure patients.

Authors:  Yong Tang; Wenbin Lu; Ziwei Zhang; Pengfei Zuo; Genshan Ma
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 10.  FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2015       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.